The goal of this clinical trial is to learn if adaptive radiation boost works to treat genitourinary cancers, esp. in the context of prostate cancer patients with post-prostatectomy local relapse and bladder cancer patients with bladder-conserving treatment. It will also learn about the safety and efficacy of adaptive boost. The main questions it aims to answer are:

Does adaptive boost lower the toxicities? Does adaptive boost maintain or improve the clinical efficacy?

Participants will:

Undergo adaptive boost on 1.5-Tesla MR-Linac Visit the clinic once every 2 weeks during RT, and every 3 months post-ART Keep a regular QOL questinnaire completion

Inclusion Criteria:

• Patients with newly diagnosed or metastatic/recurrent pathologically confirmed urological tumors, clinically assessed as suitable for adaptive radiotherapy;
• Age ≥ 18 years;
• ECOG performance status score 0-2;
• No prior radiotherapy history within the current radiation field;
• No contraindications for MRI scanning;
• No contraindications for radiotherapy.

Exclusion Criteria:

• Patients with contraindications to radiotherapy;
• Patients unable to tolerate MRI or with contraindications to MRI scanning.

Male